Viltepso

Chemical Nameviltolarsen
Dosage FormInjection (intravenous; 250 mg/5 mL, 50 mg/mL)
Drug ClassOligonucleotides
SystemMusculoskeletal
CompanyNS Pharma Inc.
Approval Year2020

Indication

  • For the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 53 skipping
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
VILTEPSO (viltolarsen) Prescribing Information. 2020NS Pharma, Inc. Paramus, NJ